• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Check-Cap Ltd.

    6/17/21 1:25:47 PM ET
    $CHEK
    Medical Electronics
    Health Care
    Get the next $CHEK alert in real time by email
    SC 13G 1 brhc10025924_sc13g.htm SC 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G

    INFORMATION STATEMENT TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b) (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (b)

    (Amendment No. __)*

    Check-Cap Ltd.
    (Name of Issuer)

    Ordinary Shares, par value NIS 2.40 per share
    (Title of Class of Securities)

    M2361E203
    (CUSIP Number)

    June 14, 2021
    (Date of Event Which Requires Filing of This Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐——Rule 13d-1(b)

    ☒——Rule 13d-1(c)

    ☐——Rule 13d-1(d)


    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No. M2361E203
    Page 2 of 6

    1
    NAMES OF REPORTING PERSONS
     
     
    GREEN FROG INVESTMENTS INC.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Panama
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    3,580,000
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    3,580,000
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,580,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.08%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    CUSIP No. M2361E203
    Page 3 of 6

    1
    NAMES OF REPORTING PERSONS
     
     
    GIOTTO LEONARDO CLOVIS GRAVIER DE FILIPPI
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    France and Italy
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    3,580,000
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    3,580,000
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,580,000
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.08%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     


    CUSIP No. M2361E203
    Page 4 of 6

    Item 1
    (a) Name of Issuer:
    Check-Cap Ltd.

    (b)       Address of Issuer's Principal Executive Offices:
    Check-Cap Building
    Abba Hushi Avenue
    P.O. Box 1271
    Isfiya, 30090, Mount Carmel, Israel

    Item 2

     
    (a) Name of Person Filing:
     
    Giotto Leonardo Clovis Gravier de Filippi
     
    Green Frog Investments Inc.
     
    (b)  Address of Principal Business Office:
     
    Marjan Island Resort, Unit 217, Ras al Khaimah, UAE
     
    PH Molon Tower, Piso 5 A, Calle Aquilino de la Guardia, El Dorado, Panama City, Panama
     
    (c)   Citizenship:
     
    France and Italy
     
    Panama

    (d)       Title of Class of Securities:
    Ordinary Shares, par value NIS 2.40 per share

    (e)       CUSIP Number:
    M2361E203

    Item 3
    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     
    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
     
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
     
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
     
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940, as amended (the “Investment Company Act”);
     
    (e)
    ☐ Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
     
    (f)
    ☐ Employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
     
    (g)
    ☐ Parent holding company or control person, in accordance with 13d-1(b)(ii)(G);
     
    (h)
    ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
     
    (i)
    ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
     
    (j)
    ☐ A non-U.S. institution in accordance with §240.13d-1(b)(ii)(J); or
     
    (k)
    ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K);

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution


    CUSIP No. M2361E203
    Page 5 of 6

    Item 4
    Ownership.1

    (a)    Amount beneficially owned: 3,580,000
    (b)     Percent of Class: 5.08%
    (c)     Number of shares as to which such person has:

    (i)  Sole power to vote or direct the vote: 3,580,000

    (ii)  Shared power to vote: 0

    (iii) Sole power to dispose or direct the disposition of: 3,580,000

    (iv) Shared power to dispose or direct the disposition of: 0

    Item 5
    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not Applicable.

    Item 8
    Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9
    Notice of Dissolution of Group.

    Not Applicable.

    Item 10
    Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    1
    The Yakima Trust, a trust organized under the laws of New Zealand, owns 100% of the shares of Green Frog Investment, Inc.  Giotto Leonardo Clovis Gravier de Filippi, an individual, is the investment manager of Green Frog Investment, Inc. for United States securities law purposes. The information shown in response to this Item 4 is applicable to each of Green Frog Investment, Inc. and Mr. de Filippi.
     

    CUSIP No. M2361E203
    Page 6 of 6

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: June 17, 2021
      
        
     
    GREEN FROG INVESTMENTS, INC.

     
    By:
    /s/ Giotto Leonardo Clovis Gravier De Filippi
     
    Name:
    Giotto Leonardo Clovis Gravier De Filippi
     
    Title:
    Investment Manager
         
     
    /s/ Giotto Leonardo Clovis Gravier De Filippi
     
    Name:
    Giotto Leonardo Clovis Gravier De Filippi



    Get the next $CHEK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHEK

    DatePrice TargetRatingAnalyst
    8/9/2021$4.00 → $3.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CHEK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MediPharm Labs Files Proxy Materials, Issues Chair's Letter to Shareholders

      TORONTO, May 13, 2025 /PRNewswire/ - MediPharm Labs Corp. (TSX:LABS) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoids, has filed its Management Information Circular ("MIC" or the "Circular") and proxy materials (the "Meeting Materials") for its upcoming Annual and Special Meeting of Shareholders, scheduled for June 16, 2025. The Meeting Materials will be sent to shareholders in the coming days, and are available on the SEDAR+ website at www.sedarplus.ca. MediPharm's Board of Directors (the "Board") recommends that shareholders vote through the GREEN proxy or GREEN voting instruction card in support of the Company's nominees for Board of Dir

      5/13/25 7:31:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Le

      5/9/25 2:08:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Apollo Technology Capital Corporation to Nominate Six Highly Qualified Directors to MediPharm Labs' Board of Directors Following Years of Shareholder Value Destruction

      Believes Board Change is Urgently Needed: Under the Current Board and Management, MediPharm Stock Price is Down More Than 99%, Costing Shareholders Nearly $1 Billion MediPharm's Board Cannot be Trusted to Create Shareholder Value or Oversee Management! Company Leadership Lacks Any Credible Strategic Plan and Has Made Numerous Reckless Acquisitions While Rewarding Themselves with Excessive Compensation for Repeated Failures Apollo's Nominees Bring Significant Turnaround, M&A, and Operational Experience in Cannabis and Adjacent Industries, and Will Execute Plan to Restore Value for ALL MediPharm Shareholders Urges MediPharm Shareholders to Vote for Wholesale Change at Annual Meeting Sends Let

      5/8/25 7:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    SEC Filings

    See more
    • SEC Form NT 20-F filed by Check-Cap Ltd.

      NT 20-F - Check-Cap Ltd (0001610590) (Filer)

      5/1/25 4:15:02 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      4/15/25 4:15:15 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form 6-K filed by Check-Cap Ltd.

      6-K - Check-Cap Ltd (0001610590) (Filer)

      12/31/24 4:15:09 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Financials

    Live finance-specific insights

    See more
    • Keystone Dental Group Granted Patent from USPTO for Nexus IOS Solution

      IRVINE, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Osteon Medical, a subsidiary of Keystone Dental Holdings ("Keystone Dental" or the "Company"), today announced the United States Patent and Trademark Office (USPTO) has granted the Company a patent for its innovative Nexus IOS solution. The Nexus iOS Scan Gauge technology allows implant dentists to perform direct full-arch implant scans using an Intraoral Scanner (IOS) with predictable and passive fitting prosthetic outcomes. This technology replaces the traditionally manual impression-taking process through a faster, cost-effective, and accessible workflow. The Nexus iOS Scan Gauge technology is now the only patented elongated body scan

      10/18/23 4:05:00 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • Keystone Dental Holdings and Check-Cap Ltd Enter into Definitive Business Combination Agreement

      Proposed business combination to create a Nasdaq-listed medical device company focused on advancing the commercial execution and market development of Keystone's comprehensive portfolio of implants, arches and other tooth replacement solutions Keystone 2022 revenues exceeded $60 million The combined company will trade on the NASDAQ with the ticker "KSD" Investor conference call and webcast scheduled for 8:30 a.m. ET on Thursday, August 17th IRVINE, Calif. and BURLINGTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Keystone Dental Holdings, Inc. ("Keystone Dental") and Check-Cap Ltd. ("Check-Cap" or the "Company") (NASDAQ:CHEK) today announced that they have entered into a definitive Busin

      8/16/23 5:08:47 PM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $3.00 from $4.00 previously

      8/9/21 6:35:25 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap downgraded by Dawson James with a new price target

      Dawson James downgraded Check-Cap from Buy to Neutral and set a new price target of $2.00

      3/17/21 12:12:30 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • HC Wainwright & Co. reiterated coverage on Check-Cap with a new price target

      HC Wainwright & Co. reiterated coverage of Check-Cap with a rating of Buy and set a new price target of $4.00 from $1.50 previously

      3/16/21 6:31:50 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      4/8/24 7:35:32 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D filed by Check-Cap Ltd.

      SC 13D - Check-Cap Ltd (0001610590) (Subject)

      4/1/24 9:26:38 PM ET
      $CHEK
      Medical Electronics
      Health Care
    • SEC Form SC 13D/A filed by Check-Cap Ltd. (Amendment)

      SC 13D/A - Check-Cap Ltd (0001610590) (Subject)

      12/18/23 6:07:13 AM ET
      $CHEK
      Medical Electronics
      Health Care

    $CHEK
    Leadership Updates

    Live Leadership Updates

    See more
    • Symetryx Today Issues Open Letter to Shareholders In Regard to the Upcoming Annual General Meeting

      Recommends Fellow Shareholders Vote AGAINST Keystone Transaction & the Check-Cap Board Nominees - Further Recommends a Vote FOR the Symetryx Slate of Director Candidates Cites Unrealistic and Aggressive Valuation of Keystone Used to Justify the Merger and Troubling Cash Burn by Check-Cap Board & Management TORONTO, Nov. 28, 2023 /PRNewswire/ - Symetryx, a holder of 5.6% of Check-Cap Ltd. (NASDAQ:CHEK) shares, today issued the following open letter to shareholders. In the letter Symetryx cites, among other items, its serious concerns and reason for voting AGAINST the proposed transaction with Keystone Dental.  Symetryx discusses its concerns around the actions of the Board in its evaluation

      11/28/23 11:56:00 AM ET
      $CHEK
      Medical Electronics
      Health Care
    • Check-Cap Appoints Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs

      ISFIYA, Israel, Sept. 1, 2021 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ:CHEK), (NASDAQ:CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced the appointment of Dr. Hanit Brenner-Lavie as Vice President of Clinical Affairs. Dr. Brenner-Lavie will be responsible for leading the Company's overall clinical strategy and implementation as well as driving the Company's clinical direction, including innovation. "Dr. Brenner-Lavie has a proven track record of clinical strategy dev

      9/1/21 8:30:00 AM ET
      $CHEK
      Medical Electronics
      Health Care